6990 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. HKEX · China

Sichuan Kelun-Biotech Biopharmaceutical Co. (6990) news

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 6990, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Sichuan Kelun-Biotech Biopharmaceutical Co. news

We have not published a story on Sichuan Kelun-Biotech Biopharmaceutical Co. yet. When there is news, it will appear here.

Questions about Sichuan Kelun-Biotech Biopharmaceutical Co.

What is the ticker symbol of Sichuan Kelun-Biotech Biopharmaceutical Co.?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. trades under the ticker 6990 on HKEX.

Where is Sichuan Kelun-Biotech Biopharmaceutical Co. listed?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is listed on HKEX.

Which country or territory is Sichuan Kelun-Biotech Biopharmaceutical Co. listed under?

Our directory records Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. under China.

What does Sichuan Kelun-Biotech Biopharmaceutical Co. do?

Our directory classifies Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Sichuan Kelun-Biotech Biopharmaceutical Co.?

The ISIN recorded for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is CNE1000062J1.

Does aibio.space cover Sichuan Kelun-Biotech Biopharmaceutical Co.?

aibio.space lists Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Sichuan Kelun-Biotech Biopharmaceutical Co.?

Companies in our directory listed in the same country and business area as Sichuan Kelun-Biotech Biopharmaceutical Co.: BIOSTAR PHARMACEUTICALS INC, Shandong Buchang Pharmaceuticals Co., Tonghua Dongbao Pharmaceutical Co., Shanghai Allist Pharmaceuticals Co., Hainan Shuangcheng Pharmaceuticals Co., Jenkem Technology Co..

Investor discussion: Sichuan Kelun-Biotech Biopharmaceutical Co.

Members talk about Sichuan Kelun-Biotech Biopharmaceutical Co. (6990). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Sichuan Kelun-Biotech Biopharmaceutical Co., newest first. Each line links the filing it comes from.

Aug 4, 2026Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION SUBSCRIPTION FOR WEALTH MANAGEMENT PRODUCT. Source
Jul 10, 2026Financings
Share or debt issue: (1) COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE AND (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION. Source
Jul 7, 2026Financings
Share or debt issue: (1) PLACING OF NEW H SHARES UNDER GENERAL MANDATE; AND (2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION. Source
Jun 30, 2026Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION SUBSCRIPTIONS FOR WEALTH MANAGEMENT PRODUCTS. Source
Jun 11, 2026Legal
Legal proceedings: VOLUNTARY ANNOUNCEMENT RECEIPT OF PAYMENT MADE BY MEDILINK THERAPEUTICS PURSUANT TO THE SETTLEMENT. Source
Jun 4, 2026Financings
Share or debt issue: CIRCULAR OF ANNUAL GENERAL MEETING. Source
Jun 3, 2026Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION SUBSCRIPTIONS FOR WEALTH MANAGEMENT PRODUCTS. Source
Apr 15, 2026Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION SUBSCRIPTIONS FOR WEALTH MANAGEMENT PRODUCTS. Source
Jan 7, 2026Mergers
Transaction under the Listing Rules: TERMINATION OF DISCLOSEABLE TRANSACTION IN RELATION TO SUBSCRIPTION FOR WEALTH MANAGEMENT PRODUCT. Source
Jan 6, 2026Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION SUBSCRIPTIONS FOR WEALTH MANAGEMENT PRODUCTS. Source
Dec 16, 2025Legal
Legal proceedings: VOLUNTARY ANNOUNCEMENT SETTLEMENT OF DISPUTES. Source
Sep 29, 2025Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION SUBSCRIPTION FOR WEALTH MANAGEMENT PRODUCT. Source
Jul 25, 2025Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS SUBSCRIPTIONS FOR WEALTH MANAGEMENT PRODUCTS. Source
Jun 12, 2025Financings
Share or debt issue: (1) COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE AND (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION. Source
Jun 4, 2025Financings
Share or debt issue: (1) PLACING OF NEW H SHARES UNDER GENERAL MANDATE; AND (2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION. Source
May 21, 2025Financings
Share or debt issue: CIRCULAR OF ANNUAL GENERAL MEETING. Source
May 8, 2025Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS ACQUISITION OF WEALTH MANAGEMENT PRODUCTS. Source
Mar 20, 2025Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS SUBSCRIPTIONS FOR STRUCTURED DEPOSITS. Source
Jan 21, 2025Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS SUBSCRIPTIONS FOR STRUCTURED DEPOSITS. Source
Dec 18, 2024Financings
Share or debt issue: (1) COMPLETION OF SUBSCRIPTION OF NEW DOMESTIC SHARES UNDER SPECIFIC MANDATE AND (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION. Source
Dec 17, 2024Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS SUBSCRIPTIONS FOR WEALTH MANAGEMENT PRODUCTS. Source
Nov 22, 2024Financings
Share or debt issue: APPROVAL FOR REGISTRATION BY THE CSRC IN RELATION TO SUBSCRIPTION OF NEW DOMESTIC SHARES UNDER SPECIFIC MANDATE. Source

Press releases

Headlines of Sichuan Kelun-Biotech Biopharmaceutical Co.'s own announcements, newest first. Each opens the full release on the newswire that carried it.

Oct 25, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT RESULTS FROM MULTIPLE STUDIES OF INNOVATIVE DRUGS AT 2026 ESMO CONGRESS
Sep 8, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT POSITIVE PHASE 2 INTERIM RESULTS AND INITIATION OF PHASE 3 STUDY OF SKB378/WIN378 IN ASTHMA
Aug 17, 2026HKEXnews
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026
Aug 4, 2026HKEXnews
DISCLOSEABLE TRANSACTION SUBSCRIPTION FOR WEALTH MANAGEMENT PRODUCT
Jul 30, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT NEW INDICATION APPLICATION FOR CORE PRODUCT TROP2 ADC SACITUZUMAB TIRUMOTECAN (sac-TMT) ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Jul 27, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW DRUG APPROVAL FOR SKB565 BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Jul 14, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT PRIMARY ENDPOINT MET FOR PHASE 3 STUDY OF CORE PRODUCT TROP2 ADC SACITUZUMAB TIRUMOTECAN (sac-TMT) IN COMBINATION WITH PEMBROLIZUMAB AS FIRST-LINE TREATMENT OF PATIENTS WITH PD-L1-NEGATIVE LOCALLY ADVANCED OR METASTATIC NON-SQUAMOUS NSCLC
Jul 10, 2026HKEXnews
ARTICLES OF ASSOCIATION
Jul 10, 2026HKEXnews
(1) COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE AND (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION
Jul 7, 2026HKEXnews
(1) PLACING OF NEW H SHARES UNDER GENERAL MANDATE; AND (2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
Jul 7, 2026HKEXnews
RESIGNATION OF JOINT COMPANY SECRETARY AND CHANGE OF AUTHORIZED REPRESENTATIVE
Jun 30, 2026HKEXnews
DISCLOSEABLE TRANSACTION SUBSCRIPTIONS FOR WEALTH MANAGEMENT PRODUCTS
Jun 29, 2026HKEXnews
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 29, 2026
Jun 11, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT RECEIPT OF PAYMENT MADE BY MEDILINK THERAPEUTICS PURSUANT TO THE SETTLEMENT
Jun 4, 2026HKEXnews
NOTICE OF ANNUAL GENERAL MEETING
Jun 4, 2026HKEXnews
CIRCULAR OF ANNUAL GENERAL MEETING
May 25, 2026HKEXnews
GRANT OF RSUs UNDER THE 2025 SHARE INCENTIVE SCHEME AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
May 21, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT RESULTS FROM MULTIPLE STUDIES OF INNOVATIVE DRUGS AT 2026 ASCO ANNUAL MEETING
May 12, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW DRUG APPROVAL FOR SKB118 BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
May 8, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT NEW INDICATION APPLICATION FOR CORE PRODUCT TROP2 ADC SACITUZUMAB TIRUMOTECAN (sac-TMT) ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:6990 on TradingView.

Listing details

Company: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Ticker: 6990
Listing: HKEX
Country or territory: China
Business scope: Pharmaceuticals: Major
ISIN: CNE1000062J1
Last quote in directory: 2026-10-22
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction